|
US5977144A
(en)
*
|
1992-08-31 |
1999-11-02 |
University Of Florida |
Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
|
|
US7214686B2
(en)
|
1997-06-30 |
2007-05-08 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
|
US6632823B1
(en)
*
|
1997-12-22 |
2003-10-14 |
Merck & Co., Inc. |
Substituted pyridine compounds useful as modulators of acetylcholine receptors
|
|
US6277870B1
(en)
|
1998-05-04 |
2001-08-21 |
Astra Ab |
Use
|
|
FR2804430B1
(fr)
*
|
2000-01-28 |
2002-03-22 |
Sanofi Synthelabo |
Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
|
|
GB0010955D0
(en)
|
2000-05-05 |
2000-06-28 |
Novartis Ag |
Organic compounds
|
|
US8914114B2
(en)
|
2000-05-23 |
2014-12-16 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
|
US6479510B2
(en)
|
2000-08-18 |
2002-11-12 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
|
US6486172B2
(en)
|
2000-08-18 |
2002-11-26 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
|
US6492386B2
(en)
*
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
EP1311505A2
(en)
*
|
2000-08-21 |
2003-05-21 |
PHARMACIA & UPJOHN COMPANY |
Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
|
|
WO2002017358A2
(en)
*
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
|
|
US6599916B2
(en)
|
2000-08-21 |
2003-07-29 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
PE20021019A1
(es)
|
2001-04-19 |
2002-11-13 |
Upjohn Co |
Grupos azabiciclicos sustituidos
|
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
|
AR036041A1
(es)
*
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
|
|
EP1419162A1
(en)
*
|
2001-08-24 |
2004-05-19 |
Pharmacia & Upjohn Company |
Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease
|
|
BR0212101A
(pt)
|
2001-08-24 |
2004-08-24 |
Pharmacia & Up John Company |
7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
|
|
JP2005527472A
(ja)
*
|
2001-09-12 |
2005-09-15 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン
|
|
HUP0402289A2
(hu)
*
|
2001-10-02 |
2005-02-28 |
Pharmacia & Upjohn Company |
Gyógyhatású azabiciklusos csoporttal helyettesített kondenzált heteroaril-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
|
|
US6849620B2
(en)
|
2001-10-26 |
2005-02-01 |
Pfizer Inc |
N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
|
|
US6919359B2
(en)
|
2001-11-08 |
2005-07-19 |
Pfizer Inc |
Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
|
|
US6951868B2
(en)
|
2001-11-09 |
2005-10-04 |
Pfizer Inc. |
Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
|
|
EP1463481A4
(en)
|
2001-12-14 |
2008-06-25 |
Targacept Inc |
METHOD AND COMPOSITIONS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
|
|
DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
|
US6852716B2
(en)
|
2002-02-15 |
2005-02-08 |
Pfizer Inc |
Substituted-aryl compounds for treatment of disease
|
|
AU2003217275A1
(en)
*
|
2002-02-19 |
2003-09-09 |
Pharmacia And Upjohn Company |
Azabicyclic compounds for the treatment of disease
|
|
JP2005523288A
(ja)
*
|
2002-02-19 |
2005-08-04 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
|
|
CA2475773A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Pharmacia & Upjohn Company |
Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
|
|
DE10211416A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Essig- und Propionsäureamide
|
|
DE10211415A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Bicyclische N-Biarylamide
|
|
EP1542999A1
(en)
|
2002-08-01 |
2005-06-22 |
Pharmacia & Upjohn Company LLC |
1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
|
|
JP2006501246A
(ja)
|
2002-08-30 |
2006-01-12 |
メモリー・ファーマシューティカルズ・コーポレイション |
神経変性疾患の治療において有用なアナバセイン誘導体
|
|
GB0220581D0
(en)
|
2002-09-04 |
2002-10-09 |
Novartis Ag |
Organic Compound
|
|
MXPA05003317A
(es)
|
2002-09-25 |
2005-07-05 |
Memory Pharm Corp |
Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
|
|
WO2004039815A2
(en)
*
|
2002-11-01 |
2004-05-13 |
Pharmacia & Upjohn Company Llc |
Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
|
|
US7238715B2
(en)
*
|
2002-12-06 |
2007-07-03 |
The Feinstein Institute For Medical Research |
Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
|
|
WO2004052365A2
(en)
|
2002-12-06 |
2004-06-24 |
North Shore-Long Island Jewish Research Institute |
Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
|
|
WO2004085433A2
(en)
*
|
2003-03-28 |
2004-10-07 |
Pharmacia & Upjohn Company Llc |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
|
GB0310867D0
(en)
|
2003-05-12 |
2003-06-18 |
Novartis Ag |
Organic compounds
|
|
DE10334724A1
(de)
|
2003-07-30 |
2005-02-24 |
Bayer Healthcare Ag |
N-Biarylamide
|
|
AU2004282201A1
(en)
|
2003-10-15 |
2005-04-28 |
Targacept, Inc. |
Azabicycyclic compounds for relieving pain and treating central nervous system disorders
|
|
FR2861076B1
(fr)
*
|
2003-10-17 |
2006-01-06 |
Sanofi Synthelabo |
Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
|
|
DE602004010299T2
(de)
|
2003-12-22 |
2008-09-18 |
Memory Pharmaceuticals Corp. |
Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
|
|
US20050137217A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
Spirocyclic quinuclidinic ether derivatives
|
|
FR2865208B1
(fr)
*
|
2004-01-16 |
2009-01-16 |
Sanofi Synthelabo |
Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
|
|
US10912712B2
(en)
|
2004-03-25 |
2021-02-09 |
The Feinstein Institutes For Medical Research |
Treatment of bleeding by non-invasive stimulation
|
|
NZ550534A
(en)
|
2004-03-25 |
2009-07-31 |
Memory Pharm Corp |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
|
|
WO2006001894A1
(en)
|
2004-04-22 |
2006-01-05 |
Memory Pharmaceutical Corporation |
Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
|
|
JP2007538011A
(ja)
|
2004-05-07 |
2007-12-27 |
メモリー・ファーマシューティカルズ・コーポレイション |
１ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
|
|
PE20060437A1
(es)
|
2004-06-18 |
2006-06-08 |
Novartis Ag |
COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
|
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
|
GB0424564D0
(en)
*
|
2004-11-05 |
2004-12-08 |
Novartis Ag |
Organic compounds
|
|
RU2418797C2
(ru)
|
2004-12-22 |
2011-05-20 |
Мемори Фармасьютиклз Корпорейшн |
Лиганды никотинового рецептора альфа-7, их получение и применение
|
|
US11207518B2
(en)
|
2004-12-27 |
2021-12-28 |
The Feinstein Institutes For Medical Research |
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
|
|
CN102793972A
(zh)
|
2004-12-27 |
2012-11-28 |
范因斯坦医学研究院 |
通过电刺激迷走神经治疗炎症性疾病
|
|
BRPI0614874A2
(pt)
|
2005-08-22 |
2011-04-19 |
Targacept Inc |
diazatricicloalcanos substituìdos com heteroarila, métodos para sua preparação e uso dos mesmos
|
|
US8106066B2
(en)
|
2005-09-23 |
2012-01-31 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
|
|
GB0521508D0
(en)
|
2005-10-21 |
2005-11-30 |
Novartis Ag |
Organic compounds
|
|
US8316104B2
(en)
|
2005-11-15 |
2012-11-20 |
California Institute Of Technology |
Method and apparatus for collaborative system
|
|
GB0525673D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
|
GB0525672D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
|
TWI405763B
(zh)
*
|
2006-11-02 |
2013-08-21 |
Targacept Inc |
菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
|
|
TW200901974A
(en)
|
2007-01-16 |
2009-01-16 |
Wyeth Corp |
Compounds, compositions, and methods of making and using them
|
|
KR20090107567A
(ko)
*
|
2007-02-09 |
2009-10-13 |
아스텔라스세이야쿠 가부시키가이샤 |
아자 가교환 화합물
|
|
TW200911808A
(en)
*
|
2007-07-23 |
2009-03-16 |
Astrazeneca Ab |
Novel compounds
|
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
|
US8391970B2
(en)
|
2007-08-27 |
2013-03-05 |
The Feinstein Institute For Medical Research |
Devices and methods for inhibiting granulocyte activation by neural stimulation
|
|
DK2217597T3
(da)
|
2007-10-01 |
2011-06-20 |
Comentis Inc |
Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
|
|
JP2011511845A
(ja)
|
2008-02-13 |
2011-04-14 |
ターガセプト，インコーポレイテッド |
アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物
|
|
US9211409B2
(en)
|
2008-03-31 |
2015-12-15 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation of T-cell activity
|
|
US9662490B2
(en)
|
2008-03-31 |
2017-05-30 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
|
|
MX2010014203A
(es)
|
2008-06-20 |
2011-02-22 |
Astrazeneca Ab |
Derivados de dibenzotiazepina y sus usos - 424.
|
|
ES2452484T3
(es)
|
2008-11-18 |
2014-04-01 |
Setpoint Medical Corporation |
Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
|
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
|
UY32397A
(es)
*
|
2009-01-28 |
2010-08-31 |
Astrazeneca Ab |
Compuestos de 2-aza-biciclo [2,2,1] heptano y sus usos
|
|
US8996116B2
(en)
|
2009-10-30 |
2015-03-31 |
Setpoint Medical Corporation |
Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
|
|
US9211410B2
(en)
|
2009-05-01 |
2015-12-15 |
Setpoint Medical Corporation |
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
|
WO2010144578A2
(en)
|
2009-06-09 |
2010-12-16 |
Setpoint Medical Corporation |
Nerve cuff with pocket for leadless stimulator
|
|
FR2948368B1
(fr)
*
|
2009-07-21 |
2011-07-22 |
Servier Lab |
Nouveaux composes piperidiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
WO2014169145A1
(en)
|
2013-04-10 |
2014-10-16 |
Setpoint Medical Corporation |
Closed-loop vagus nerve stimulation
|
|
US9833621B2
(en)
|
2011-09-23 |
2017-12-05 |
Setpoint Medical Corporation |
Modulation of sirtuins by vagus nerve stimulation
|
|
CN105126248B
(zh)
|
2009-12-23 |
2018-06-12 |
赛博恩特医疗器械公司 |
用于治疗慢性炎症的神经刺激设备和系统
|
|
AR081402A1
(es)
|
2010-05-17 |
2012-08-29 |
Envivo Pharmaceuticals Inc |
Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
|
|
JP6250394B2
(ja)
|
2010-08-19 |
2017-12-20 |
バック・インスティテュート・フォー・リサーチ・オン・エイジング |
軽度の認知障害（ｍｃｉ）および関連障害の処置方法
|
|
EP2707094B1
(en)
|
2011-05-09 |
2016-02-03 |
Setpoint Medical Corporation |
Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
|
US12172017B2
(en)
|
2011-05-09 |
2024-12-24 |
Setpoint Medical Corporation |
Vagus nerve stimulation to treat neurodegenerative disorders
|
|
GB201111705D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Compounds and their use
|
|
GB201111704D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Novel compounds
|
|
JO3115B1
(ar)
|
2011-08-22 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مركبات بيريدازينون واستخدامها كمثبطات daao
|
|
US9572983B2
(en)
|
2012-03-26 |
2017-02-21 |
Setpoint Medical Corporation |
Devices and methods for modulation of bone erosion
|
|
CA2872005A1
(en)
|
2012-05-08 |
2013-11-14 |
Forum Pharmaceuticals, Inc. |
Methods of maintaining, treating or improving cognitive function
|
|
GB201209587D0
(en)
|
2012-05-30 |
2012-07-11 |
Takeda Pharmaceutical |
Therapeutic compounds
|
|
MA37975B2
(fr)
*
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
|
WO2014122474A1
(en)
|
2013-02-07 |
2014-08-14 |
Takeda Pharmaceutical Company Limited |
Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
|
|
TWI649317B
(zh)
*
|
2013-03-15 |
2019-02-01 |
健臻公司 |
製備葡糖基神經醯胺合成酶抑制劑之方法
|
|
HK1219722A1
(zh)
|
2013-06-21 |
2017-04-13 |
Takeda Pharmaceutical Company Limited |
1-磺酰基派啶衍生物作为前动力蛋白受体的调节剂
|
|
GB201314286D0
(en)
|
2013-08-08 |
2013-09-25 |
Takeda Pharmaceutical |
Therapeutic Compounds
|
|
GB201318222D0
(en)
|
2013-10-15 |
2013-11-27 |
Takeda Pharmaceutical |
Novel compounds
|
|
GB201320905D0
(en)
|
2013-11-27 |
2014-01-08 |
Takeda Pharmaceutical |
Therapeutic compounds
|
|
TW201613864A
(en)
|
2014-02-20 |
2016-04-16 |
Takeda Pharmaceutical |
Novel compounds
|
|
US20170166561A1
(en)
|
2014-07-11 |
2017-06-15 |
Alpharmagen, Llc |
Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity
|
|
US11311725B2
(en)
|
2014-10-24 |
2022-04-26 |
Setpoint Medical Corporation |
Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
|
|
US11406833B2
(en)
|
2015-02-03 |
2022-08-09 |
Setpoint Medical Corporation |
Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
|
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
|
US10596367B2
(en)
|
2016-01-13 |
2020-03-24 |
Setpoint Medical Corporation |
Systems and methods for establishing a nerve block
|
|
CN108882885A
(zh)
|
2016-01-20 |
2018-11-23 |
赛博恩特医疗器械公司 |
迷走神经刺激的控制
|
|
US11471681B2
(en)
|
2016-01-20 |
2022-10-18 |
Setpoint Medical Corporation |
Batteryless implantable microstimulators
|
|
US10314501B2
(en)
|
2016-01-20 |
2019-06-11 |
Setpoint Medical Corporation |
Implantable microstimulators and inductive charging systems
|
|
US10583304B2
(en)
|
2016-01-25 |
2020-03-10 |
Setpoint Medical Corporation |
Implantable neurostimulator having power control and thermal regulation and methods of use
|
|
GB201616839D0
(en)
|
2016-10-04 |
2016-11-16 |
Takeda Pharmaceutical Company Limited |
Therapeutic compounds
|
|
GB201619514D0
(en)
|
2016-11-18 |
2017-01-04 |
Takeda Pharmaceuticals Co |
Novel compounds
|
|
DE102017210141A1
(de)
|
2017-06-16 |
2018-12-20 |
Henkel Ag & Co. Kgaa |
Portion zur Bereitstellung tensidhaltiger Flotten
|
|
US11173307B2
(en)
|
2017-08-14 |
2021-11-16 |
Setpoint Medical Corporation |
Vagus nerve stimulation pre-screening test
|
|
US11660443B2
(en)
|
2018-04-20 |
2023-05-30 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
|
|
US11260229B2
(en)
|
2018-09-25 |
2022-03-01 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
|
|
CN114040762A
(zh)
|
2019-02-04 |
2022-02-11 |
建新公司 |
使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
|
|
US12343535B2
(en)
|
2019-04-12 |
2025-07-01 |
Setpoint Medical Corporation |
Vagus nerve stimulation to treat neurodegenerative disorders
|
|
CN114746422B
(zh)
*
|
2019-11-15 |
2024-03-12 |
柳韩洋行 |
具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐以及包含它们的药物组合物
|
|
PL4041733T3
(pl)
|
2019-11-15 |
2024-09-23 |
Yuhan Corporation |
Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające
|
|
AU2021207815B2
(en)
|
2020-01-13 |
2026-03-26 |
The Feinstein Institutes For Medical Research |
Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
|
|
TW202142236A
(zh)
|
2020-02-03 |
2021-11-16 |
美商健臻公司 |
用於治療與溶體儲積症相關的神經症狀之方法
|
|
JP2021138648A
(ja)
|
2020-03-04 |
2021-09-16 |
武田薬品工業株式会社 |
経口固形製剤
|
|
US11938324B2
(en)
|
2020-05-21 |
2024-03-26 |
The Feinstein Institutes For Medical Research |
Systems and methods for vagus nerve stimulation
|
|
KR20230043024A
(ko)
|
2020-07-24 |
2023-03-30 |
젠자임 코포레이션 |
벤글루스타트를 포함하는 제약 조성물
|
|
IL306116A
(en)
*
|
2021-05-11 |
2023-11-01 |
Yuhan Corp |
New compounds with inhibitory activity against glucosylceramide synthase or an acceptable pharmaceutical salt thereof, processes for their preparation and pharmaceutical preparations containing them
|
|
WO2022245878A1
(en)
|
2021-05-17 |
2022-11-24 |
Setpoint Medical Corporation |
Neurostimulation parameter authentication and expiration system for neurostimulation
|
|
US20250229086A1
(en)
|
2022-01-20 |
2025-07-17 |
Setpoint Medical Corporation |
Treatment of inflammatory disorders
|
|
CA3268132A1
(en)
*
|
2022-10-24 |
2024-05-02 |
Yuhan Corporation |
NEW DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE SALT AND ITS PREPARATION PROCESSES
|
|
JP2025534728A
(ja)
*
|
2022-10-24 |
2025-10-17 |
ユーハン・コーポレイション |
ジメチル－２，３－ジヒドロ－１ｈ－インデン誘導体の改良された製造方法
|
|
KR20250117295A
(ko)
*
|
2024-01-26 |
2025-08-04 |
주식회사유한양행 |
고셔병의 예방 또는 치료용 약제학적 조성물
|
|
GB202414197D0
(en)
|
2024-09-27 |
2024-11-13 |
Addex Pharmaceuticals Sa |
Novel compounds
|
|
GB202414193D0
(en)
|
2024-09-27 |
2024-11-13 |
Addex Pharmaceuticals Sa |
Novel compounds
|